The short answer
Tirzepatide is a 39-residue synthetic peptide that activates both the GIP and GLP-1 receptors from a single molecule, the first dual incretin agonist to reach the market. Built on a modified GIP backbone with a C20 fatty diacid for weekly dosing, it reported up to 22.5% weight reduction over 72 weeks in SURMOUNT-1.
Key facts
- Class
- Dual GIP / GLP-1 receptor agonist
- Developer
- Eli Lilly
- Residues
- 39 amino acids
- Molecular weight
- ~4,813 Da
- Molecular formula
- C225H348N48O68
- PubChem CID
- 156588324
- Backbone
- Modified GIP scaffold
- Brands
- Mounjaro, Zepbound
Why a GIP backbone rather than a GLP-1 one
This is the design decision that defines tirzepatide. Rather than starting from GLP-1 and adding GIP activity, Lilly started from GIP and engineered in GLP-1 receptor binding. The resulting molecule is a full GIP receptor agonist with somewhat weaker GLP-1 activity relative to native GLP-1: an imbalanced dual agonist by design, not an evenly split one. Retatrutide later used the same GIP-scaffold strategy to add a third receptor.
What GIP adds
Glucose-dependent insulinotropic polypeptide is the other major incretin hormone, and it accounts for a substantial share of the incretin effect in healthy physiology. Its contribution to weight reduction is still debated. GIP receptor agonism and antagonism have both been argued to help, which is an unusual state for a field to be in. What is not in dispute is the empirical result: adding GIP activity to GLP-1 activity produces more reduction than GLP-1 alone.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
SURMOUNT-1 and the estimand distinction
SURMOUNT-1 ran 72 weeks testing 5 mg, 10 mg and 15 mg once weekly. It is commonly quoted two different ways. On the treatment-regimen estimand, covering everyone randomised, 10 mg produced 19.5% and 15 mg 20.9%. On the efficacy estimand, covering those who adhered, the same arms produced 21.4% and 22.5%. Both sets appear in the literature; the higher pair is quoted far more often. Published in the New England Journal of Medicine in June 2022.
Head to head against semaglutide
SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes to maximum tolerated tirzepatide (10 or 15 mg) or maximum tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks. Tirzepatide produced 20.2% mean reduction against semaglutide's 13.7%, and 18.4 cm waist reduction against 13.0 cm, both significant at p<0.001. Gastrointestinal adverse events causing discontinuation were lower on tirzepatide at 2.7% than semaglutide at 5.6%.
Where it sits in the landscape
Tirzepatide is currently the most effective incretin with a marketing authorisation. Compounds reporting larger figures (retatrutide at 28.3%, CagriSema at 22.7%) are investigational or under review. It is marketed as Mounjaro for type 2 diabetes and Zepbound for weight management.
Frequently asked questions
Is tirzepatide a GLP-1 drug?
It is more than one. Tirzepatide activates both the GIP and GLP-1 receptors, which is why it is described as a dual agonist rather than a GLP-1 agonist.
Why is SURMOUNT-1 quoted as both 20.9% and 22.5%?
Different estimands. 20.9% covers everyone randomised on 15 mg; 22.5% covers those who adhered to treatment.
Is tirzepatide better than semaglutide?
On weight reduction, SURMOUNT-5 showed a clear head-to-head advantage: 20.2% against 13.7% at 72 weeks. Semaglutide has the larger cardiovascular outcome evidence base.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSURMOUNT-1: Tirzepatide once weekly for obesity. NEJM 2022 (PMID 35658024)pubmed.ncbi.nlm.nih.gov
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide. NEJMnejm.org
- RefSURMOUNT-5 journal scan: American College of Cardiologyacc.org
- PubChemPubChem · Tirzepatide (CID 156588324)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Semaglutide vs Tirzepatide: What the Direct Comparison ShowedSURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7% mean reduction. The full comparison, including tolerability.
- What Is the Incretin Effect?Oral glucose produces far more insulin than the same glucose given intravenously. That gap is the incretin effect, and this whole drug class exploits it.
- DPP-4: Why Native Incretins Last Two MinutesDPP-4 removes two residues from GLP-1 and inactivates it within minutes. How Aib8 substitution and albumin binding defeat it, and why small molecules ignore it.
- GLP-1 Drugs Beyond Weight LossSELECT showed a 20% reduction in cardiovascular events. Heart failure, kidney and peripheral artery indications followed. What the evidence supports.
- The GIP Paradox: Why Agonism and Antagonism Both Produce Weight LossTirzepatide activates the GIP receptor. MariTide blocks it. Both produce substantial weight loss alongside GLP-1 agonism, and the field has not resolved why.